Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • AMD
  • DME
  • Uveitis
  • Diabetic Retinopathy
  • Ophthalmology Times
MJH Life Sciences

SUBSCRIBE: eNewsletter

Michelle Dalton, ELS

Diabetic eye disease: Best treatment options for your patients

November 13, 2018
  • Michelle Dalton, ELS

Although a number of medical treatment advances for diabetic retinopathy (DR) and diabetic macular edema (DME) have occurred in recent years—predominantly through the introduction of the anti-vascular endothelial growth factor (VEGF) agen

  • READ >>

Lessons learned from DRCR.net protocols

November 13, 2018
  • Michelle Dalton, ELS

This year’s Retina Subspecialty Day at the American Academy of Ophthalmology meeting included a session devoted to diabetes—most of which highlighted study data from the Diabetic Retinopathy Clinical Research Network (DRCR.net).

  • READ >>

November is Diabetic Eye Disease Awareness Month

November 6, 2018
  • Michelle Dalton, ELS

November has been declared by Prevent Blindness as Diabetic Eye Disease Awareness Month to educate the public on the effects of diabetes on vision, risk factors and treatment options.

  • READ >>

DME: What it is and how to treat it

November 5, 2018
  • Michelle Dalton, ELS

The Centers for Disease Control estimates that more than 84 million U.S. adults, or 40% of the U.S. adult population, is prediabetic.

  • READ >>

Commercial cell therapy clinics yield little evidence

October 22, 2018
  • Michelle Dalton, ELS

Research finds limited publications and dearth of information about side effects

  • READ >>

Imaging and Retinal Disorders

October 19, 2018
  • Michelle Dalton, ELS

Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections

  • READ >>

A study shows Alzheimer’s disease biomarkers in the vitreous

October 7, 2018
  • Michelle Dalton, ELS

Alzheimer’s disease leads to severe cognitive dysfunction and eventual death; by 2050 it is expected to affect more than 115 million people worldwide. From time of diagnosis until death the average survival time is just under 5 years.

  • READ >>

OCTA may be harbinger of anti-VEGF efficacy

September 26, 2018
  • Michelle Dalton, ELS

When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.

  • READ >>

Anti-VEGFs can improve DRSS in majority of patients

September 14, 2018
  • Michelle Dalton, ELS

Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result i

  • READ >>

Targeted therapy for ocular melanoma

August 23, 2018
  • Michelle Dalton, ELS
  • Amy C. Schefler, MD

Light-activated AU-011 has the potential to be the first targeted therapy ever developed for the primary treatment of ocular

  • READ >>

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • AMD Awareness
  • DME
  • AMD Nurturing Program
  • Diabetic Eye Awareness
  • Wet AMD
Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".